Lasofoxifene Effective for Dyspareunia
Dyspareunia is a significant problem in postmenopausal women. A recent study at George Washington University found that up to 92% of sexually active women reported moderate or severe symptoms. Forty percent of women cited dyspareunia as their most bothersome problem associated with vaginal atrophy. A recent Phase III trial showed that lasofoxifene can significantly improve the symptoms of dyspareunia as well as increase bone mineral density (BMD) in postmenopausal women.
Adverse pregnancy outcomes linked to midlife cardiovascular disease risk
September 11th 2024In a recent study presented at the 2024 Annual Meeting of The Menopause Society, women with certain adverse outcomes during pregnancy had an increased risk of cardiovascular disease later in life.
Read More
